Summary
Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.
The global Pulmonary Hypertension Drugs market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.
Based on the type of product, the global Pulmonary Hypertension Drugs market segmented into
Prostacyclin and prostacyclin analogs
Endothelin receptor antagonists (ERAs)
Phosphodiesterase-5 (PDE-5) inhibitors
Soluble guanylate cyclase (sGC) stimulators
Based on the end-use, the global Pulmonary Hypertension Drugs market classified into
Early-stage Drug Candidates (Phase I & Phase II)
Late-stage Drug Candidates (Phase III & Registration Phase)
Based on geography, the global Pulmonary Hypertension Drugs market segmented into
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]
And the major players included in the report are
Bayer
GSK
Arena
Actelion
Pfizer
United Therapeutics
Gilead Sciences
Lung Biotechnology PBC
Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.
The global Pulmonary Hypertension Drugs market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.
Based on the type of product, the global Pulmonary Hypertension Drugs market segmented into
Prostacyclin and prostacyclin analogs
Endothelin receptor antagonists (ERAs)
Phosphodiesterase-5 (PDE-5) inhibitors
Soluble guanylate cyclase (sGC) stimulators
Based on the end-use, the global Pulmonary Hypertension Drugs market classified into
Early-stage Drug Candidates (Phase I & Phase II)
Late-stage Drug Candidates (Phase III & Registration Phase)
Based on geography, the global Pulmonary Hypertension Drugs market segmented into
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]
And the major players included in the report are
Bayer
GSK
Arena
Actelion
Pfizer
United Therapeutics
Gilead Sciences
Lung Biotechnology PBC
Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL PULMONARY HYPERTENSION DRUGS INDUSTRY
2.1 Summary about Pulmonary Hypertension Drugs Industry
2.2 Pulmonary Hypertension Drugs Market Trends
2.2.1 Pulmonary Hypertension Drugs Production & Consumption Trends
2.2.2 Pulmonary Hypertension Drugs Demand Structure Trends
2.3 Pulmonary Hypertension Drugs Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Prostacyclin and prostacyclin analogs
4.2.2 Endothelin receptor antagonists (ERAs)
4.2.3 Phosphodiesterase-5 (PDE-5) inhibitors
4.2.4 Soluble guanylate cyclase (sGC) stimulators
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Early-stage Drug Candidates (Phase I & Phase II)
4.3.2 Late-stage Drug Candidates (Phase III & Registration Phase)
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Prostacyclin and prostacyclin analogs
5.2.2 Endothelin receptor antagonists (ERAs)
5.2.3 Phosphodiesterase-5 (PDE-5) inhibitors
5.2.4 Soluble guanylate cyclase (sGC) stimulators
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Early-stage Drug Candidates (Phase I & Phase II)
5.3.2 Late-stage Drug Candidates (Phase III & Registration Phase)
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Prostacyclin and prostacyclin analogs
6.2.2 Endothelin receptor antagonists (ERAs)
6.2.3 Phosphodiesterase-5 (PDE-5) inhibitors
6.2.4 Soluble guanylate cyclase (sGC) stimulators
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Early-stage Drug Candidates (Phase I & Phase II)
6.3.2 Late-stage Drug Candidates (Phase III & Registration Phase)
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Prostacyclin and prostacyclin analogs
7.2.2 Endothelin receptor antagonists (ERAs)
7.2.3 Phosphodiesterase-5 (PDE-5) inhibitors
7.2.4 Soluble guanylate cyclase (sGC) stimulators
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Early-stage Drug Candidates (Phase I & Phase II)
7.3.2 Late-stage Drug Candidates (Phase III & Registration Phase)
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Prostacyclin and prostacyclin analogs
8.2.2 Endothelin receptor antagonists (ERAs)
8.2.3 Phosphodiesterase-5 (PDE-5) inhibitors
8.2.4 Soluble guanylate cyclase (sGC) stimulators
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Early-stage Drug Candidates (Phase I & Phase II)
8.3.2 Late-stage Drug Candidates (Phase III & Registration Phase)
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Prostacyclin and prostacyclin analogs
9.2.2 Endothelin receptor antagonists (ERAs)
9.2.3 Phosphodiesterase-5 (PDE-5) inhibitors
9.2.4 Soluble guanylate cyclase (sGC) stimulators
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Early-stage Drug Candidates (Phase I & Phase II)
9.3.2 Late-stage Drug Candidates (Phase III & Registration Phase)
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Bayer
10.1.2 GSK
10.1.3 Arena
10.1.4 Actelion
10.1.5 Pfizer
10.1.6 United Therapeutics
10.1.7 Gilead Sciences
10.1.8 Lung Biotechnology PBC
10.2 Pulmonary Hypertension Drugs Sales Date of Major Players (2017-2020e)
10.2.1 Bayer
10.2.2 GSK
10.2.3 Arena
10.2.4 Actelion
10.2.5 Pfizer
10.2.6 United Therapeutics
10.2.7 Gilead Sciences
10.2.8 Lung Biotechnology PBC
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL PULMONARY HYPERTENSION DRUGS INDUSTRY
2.1 Summary about Pulmonary Hypertension Drugs Industry
2.2 Pulmonary Hypertension Drugs Market Trends
2.2.1 Pulmonary Hypertension Drugs Production & Consumption Trends
2.2.2 Pulmonary Hypertension Drugs Demand Structure Trends
2.3 Pulmonary Hypertension Drugs Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Prostacyclin and prostacyclin analogs
4.2.2 Endothelin receptor antagonists (ERAs)
4.2.3 Phosphodiesterase-5 (PDE-5) inhibitors
4.2.4 Soluble guanylate cyclase (sGC) stimulators
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Early-stage Drug Candidates (Phase I & Phase II)
4.3.2 Late-stage Drug Candidates (Phase III & Registration Phase)
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Prostacyclin and prostacyclin analogs
5.2.2 Endothelin receptor antagonists (ERAs)
5.2.3 Phosphodiesterase-5 (PDE-5) inhibitors
5.2.4 Soluble guanylate cyclase (sGC) stimulators
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Early-stage Drug Candidates (Phase I & Phase II)
5.3.2 Late-stage Drug Candidates (Phase III & Registration Phase)
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Prostacyclin and prostacyclin analogs
6.2.2 Endothelin receptor antagonists (ERAs)
6.2.3 Phosphodiesterase-5 (PDE-5) inhibitors
6.2.4 Soluble guanylate cyclase (sGC) stimulators
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Early-stage Drug Candidates (Phase I & Phase II)
6.3.2 Late-stage Drug Candidates (Phase III & Registration Phase)
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Prostacyclin and prostacyclin analogs
7.2.2 Endothelin receptor antagonists (ERAs)
7.2.3 Phosphodiesterase-5 (PDE-5) inhibitors
7.2.4 Soluble guanylate cyclase (sGC) stimulators
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Early-stage Drug Candidates (Phase I & Phase II)
7.3.2 Late-stage Drug Candidates (Phase III & Registration Phase)
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Prostacyclin and prostacyclin analogs
8.2.2 Endothelin receptor antagonists (ERAs)
8.2.3 Phosphodiesterase-5 (PDE-5) inhibitors
8.2.4 Soluble guanylate cyclase (sGC) stimulators
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Early-stage Drug Candidates (Phase I & Phase II)
8.3.2 Late-stage Drug Candidates (Phase III & Registration Phase)
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Prostacyclin and prostacyclin analogs
9.2.2 Endothelin receptor antagonists (ERAs)
9.2.3 Phosphodiesterase-5 (PDE-5) inhibitors
9.2.4 Soluble guanylate cyclase (sGC) stimulators
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Early-stage Drug Candidates (Phase I & Phase II)
9.3.2 Late-stage Drug Candidates (Phase III & Registration Phase)
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Bayer
10.1.2 GSK
10.1.3 Arena
10.1.4 Actelion
10.1.5 Pfizer
10.1.6 United Therapeutics
10.1.7 Gilead Sciences
10.1.8 Lung Biotechnology PBC
10.2 Pulmonary Hypertension Drugs Sales Date of Major Players (2017-2020e)
10.2.1 Bayer
10.2.2 GSK
10.2.3 Arena
10.2.4 Actelion
10.2.5 Pfizer
10.2.6 United Therapeutics
10.2.7 Gilead Sciences
10.2.8 Lung Biotechnology PBC
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
